Jill D. Martin

Array ( [id] => 3940071 [patent_doc_number] => 05872154 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-02-16 [patent_title] => 'Method of reducing an immune response to a recombinant adenovirus' [patent_app_type] => 1 [patent_app_number] => 8/394032 [patent_app_country] => US [patent_app_date] => 1995-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 15 [patent_no_of_words] => 6768 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/872/05872154.pdf [firstpage_image] =>[orig_patent_app_number] => 394032 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3979133 [patent_doc_number] => 05917122 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-06-29 [patent_title] => 'Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic mice' [patent_app_type] => 1 [patent_app_number] => 8/392771 [patent_app_country] => US [patent_app_date] => 1995-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 28 [patent_no_of_words] => 12410 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/917/05917122.pdf [firstpage_image] =>[orig_patent_app_number] => 392771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4218147 [patent_doc_number] => 06040172 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-03-21 [patent_title] => 'Defective DNA viral vector comprising a neural tissue-specific promoter for in vivo expression of a gene' [patent_app_type] => 1 [patent_app_number] => 8/381924 [patent_app_country] => US [patent_app_date] => 1995-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 6355 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/040/06040172.pdf [firstpage_image] =>[orig_patent_app_number] => 381924 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4357433 [patent_doc_number] => 06255113 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-07-03 [patent_title] => 'Homologous sequence targeting in eukaryotic cells' [patent_app_type] => 1 [patent_app_number] => 8/385713 [patent_app_country] => US [patent_app_date] => 1995-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 21 [patent_no_of_words] => 19722 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/255/06255113.pdf [firstpage_image] =>[orig_patent_app_number] => 385713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3723182 [patent_doc_number] => 05681746 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-10-28 [patent_title] => 'Retroviral delivery of full length factor VIII' [patent_app_type] => 1 [patent_app_number] => 8/366851 [patent_app_country] => US [patent_app_date] => 1994-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 27391 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/681/05681746.pdf [firstpage_image] =>[orig_patent_app_number] => 366851 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4096347 [patent_doc_number] => 06096716 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-08-01 [patent_title] => 'Liposome-mediated transfection of central nervous system cells' [patent_app_type] => 1 [patent_app_number] => 8/353901 [patent_app_country] => US [patent_app_date] => 1994-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 27 [patent_no_of_words] => 27601 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/096/06096716.pdf [firstpage_image] =>[orig_patent_app_number] => 353901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4159357 [patent_doc_number] => 06107543 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-08-22 [patent_title] => 'Culture of totipotent embryonic inner cells mass cells and production of bovine animals' [patent_app_type] => 1 [patent_app_number] => 8/348769 [patent_app_country] => US [patent_app_date] => 1994-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 6 [patent_no_of_words] => 11542 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/107/06107543.pdf [firstpage_image] =>[orig_patent_app_number] => 348769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4187064 [patent_doc_number] => 06093699 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-07-25 [patent_title] => 'Method for gene therapy involving suppression of an immune response' [patent_app_type] => 1 [patent_app_number] => 8/339245 [patent_app_country] => US [patent_app_date] => 1994-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 14295 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/093/06093699.pdf [firstpage_image] =>[orig_patent_app_number] => 339245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4187559 [patent_doc_number] => 06153427 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-11-28 [patent_title] => 'Erythropoietin-inducible, erythroid-specific DNA construct' [patent_app_type] => 1 [patent_app_number] => 8/321686 [patent_app_country] => US [patent_app_date] => 1994-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 4199 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/153/06153427.pdf [firstpage_image] =>[orig_patent_app_number] => 321686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3909998 [patent_doc_number] => 06001644 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-12-14 [patent_title] => 'Mammalian transformation complex comprising a lipid carrier and DNA encoding CFTR' [patent_app_type] => 1 [patent_app_number] => 8/256004 [patent_app_country] => US [patent_app_date] => 1994-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 76 [patent_figures_cnt] => 27 [patent_no_of_words] => 25065 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/001/06001644.pdf [firstpage_image] =>[orig_patent_app_number] => 256004 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4410334 [patent_doc_number] => 06172278 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-01-09 [patent_title] => 'Ikaros transgenic cells and mice' [patent_app_type] => 1 [patent_app_number] => 8/283300 [patent_app_country] => US [patent_app_date] => 1994-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 29192 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 252 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/172/06172278.pdf [firstpage_image] =>[orig_patent_app_number] => 283300 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3785128 [patent_doc_number] => 05736387 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-04-07 [patent_title] => 'Envelope fusion vectors for use in gene delivery' [patent_app_type] => 1 [patent_app_number] => 8/244469 [patent_app_country] => US [patent_app_date] => 1994-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 18955 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/736/05736387.pdf [firstpage_image] =>[orig_patent_app_number] => 244469 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3973963 [patent_doc_number] => 05916778 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-06-29 [patent_title] => 'Diagnostics based on a glaucoma causing gene' [patent_app_type] => 1 [patent_app_number] => 8/234218 [patent_app_country] => US [patent_app_date] => 1994-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 5886 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/916/05916778.pdf [firstpage_image] =>[orig_patent_app_number] => 234218 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3651763 [patent_doc_number] => 05639939 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-06-17 [patent_title] => 'Chimeric immunocompromised mammal comprosing vascularized fetal organ tissue' [patent_app_type] => 1 [patent_app_number] => 8/205053 [patent_app_country] => US [patent_app_date] => 1994-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13124 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/639/05639939.pdf [firstpage_image] =>[orig_patent_app_number] => 205053 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4110139 [patent_doc_number] => 06023011 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-02-08 [patent_title] => 'Corticotropin-releasing factor overproducing transgenic mice' [patent_app_type] => 1 [patent_app_number] => 8/068754 [patent_app_country] => US [patent_app_date] => 1993-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 8434 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/023/06023011.pdf [firstpage_image] =>[orig_patent_app_number] => 068754 [rel_patent_id] =>[rel_patent_doc_number] =>)